MARIETTA, Ga., May 3, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws in a […]
MiMedx Comments on Flawed Osiris Data Review
MARIETTA, Ga., May 3, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws in a […]
Previous post
Spinal Simplicity Lands Investor In Nueterra Capital, Advances Opportunity For FDA-Cleared Minuteman Fusion DeviceNext post
First Ray Receives FDA 510(k) Clearance for Stealth Staple™